GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioVaxys Technology Corp (OTCPK:BVAXF) » Definitions » Price-to-Funds-From-Operations

BVAXF (BioVaxys Technology) Price-to-Funds-From-Operations : (As of Apr. 23, 2025)


View and export this data going back to 2018. Start your Free Trial

What is BioVaxys Technology Price-to-Funds-From-Operations?

Price-to-Funds-From-Operations only applies to REITs.


BioVaxys Technology Business Description

Traded in Other Exchanges
Address
595 Howe Street, Suite 303, Vancouver, BC, CAN, V6C 2T5
BioVaxys Technology Corp is a clinical-stage biopharmaceutical company dedicated to improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix 'neoantigen' tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization, and other immunological fields. The company's clinical stage pipeline includes maveropepimut-S which is in Phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its proprietary HapTenix 'neoantigen' tumor cell construct platform which is soon to enter Phase I in Spain for treating refractive late-stage ovarian cancer.